Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%
KB

Krystal Biotech, Inc. (KRYS)

NASDAQ • Healthcare

$315.33
+$16.78 (+5.6%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$297.6
Day Range$297.6 - $316.62
Avg. Volume (3M)312.9K
Market Cap$9.3B
P/E Ratio41.2
52 Week Range
$203.17$382.54
Next EarningsIn 89 daysFeb 16, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$127.3M100%
Gross Profitminus cost of goods$119.7M94%
Operating Incomeminus R&D and overhead$71.1M56%
Net Incomeminus taxes and the rest$63M50%

In plain terms: out of every $100 in revenue, Krystal Biotech, Inc. keeps $50 as net profit.

Fundamentals & Financials

Revenue (TTM)
$470M
Net Income (TTM)
$225.1M
EPS (TTM)
$7.66
ROA (TTM)
14.2%
Current Ratio
7.89

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+26.2%Q2 2026$1.83
+5.3%Q3 2026$1.79
+14.5%Q4 2026$2.05
Next

Feb 16

in 89 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +14.5%

Krystal Biotech topped consensus on both the top and bottom line in the third fiscal quarter of 2026, reported November 2, 2026, with EPS of $2.05 topping the $1.79 estimate (+14.5%) as revenue of $127.3 million topped the $125.8 million consensus (+1.2%). Revenue rose ~30% to about $127.3 million (up from roughly $97.8 million a year ago), reflecting continued commercial momentum around its gene-therapy franchise, while EPS fell ~23% from $2.66 a year ago despite the beat versus expectations. Profitability remained high, with gross margin near 94% on roughly $119.8 million of gross profit and operating margin around 56% alongside about $71.1 million of operating income. Net income declined ~21% year over year to about $63.1 million (down from roughly $79.4 million), even as the company generated operating cash flow of about $91.2 million. For the next period, consensus calls for EPS of $1.91 on revenue of $133.4 million.

View full earnings history

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a NASDAQ-listed biotechnology company developing redosable gene therapies in the United States, with a focus on severe orphan diseases. The company generated $389.1 million in FY2025 revenue and centers its programs on genetic medicines for dermatology and other serious conditions.

Name
Krystal Biotech, Inc.
CEO
Krish S. Krishnan
Industry
Healthcare
Year Founded
2015
Employees
295

Today's Snapshot

AI-generated

KRYS closed 5.6% above yesterday's close, outperforming a weaker sector.

Trading Volume

Above 10d avg 220.6K

286.3K

vs S&P 500 Today

Strong Outperformance

+5.88%

Updated: November 18, 2026 at 21:19 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
KRYS registers a neutral stance because short-term momentum and longer-term averages are offering mixed signals across timeframes. The price sits above the 10–20 period averages yet below several 50–100 moving averages while remaining modestly above the 200-day level, creating an ambiguous structure. Momentum indicators are centered with RSI near 51 and MACD modestly negative, and ADX around 18 points to a lack of clear trend. Volume is mildly positive on OBV and volatility is moderate with ATR near $11. Technical takeaway: neutral — short-term support but no decisive trend confirmation.
All signals
  • EMA (5 indicators)$303.45 - $322.76
    Buy
  • RSI (14)51.35
    Neutral
  • Stochastic %K (14, 3, 3)43.98
    Neutral
  • MACD Level (12, 26)-5.72
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.